Skip to content
TrialScanner

NCT06400303

KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

Phase 1/Phase 2TerminatedKYTXLead

Registry record

Lead sponsor
Kyverna Therapeutics
Conditions
Systemic Sclerosis; Systemic Sclerosis - Diffuse Cutaneous; Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
Primary completion
Jun 16, 2026Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT06400303 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT06400303: KYSA-5: A Study of Anti-CD19... | TrialScanner